280 related articles for article (PubMed ID: 34575299)
1. How to Protect Ovarian Function before and during Chemotherapy?
Arecco L; Ruelle T; Martelli V; Boutros A; Latocca MM; Spinaci S; Marrocco C; Massarotti C; Lambertini M
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575299
[TBL] [Abstract][Full Text] [Related]
2. Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Lambertini M; Richard F; Nguyen B; Viglietti G; Villarreal-Garza C
Clin Med Insights Reprod Health; 2019; 13():1179558119828393. PubMed ID: 30886529
[TBL] [Abstract][Full Text] [Related]
3. Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review.
Poggio F; Lambertini M; Bighin C; Conte B; Blondeaux E; D'Alonzo A; Dellepiane C; Buzzatti G; Molinelli C; Boccardo F; Del Mastro L
Clin Med Insights Reprod Health; 2019; 13():1179558119864584. PubMed ID: 31391786
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract][Full Text] [Related]
5. The role of gonadotropin-releasing hormone agonists in female fertility preservation.
Lee JH; Choi YS
Clin Exp Reprod Med; 2021 Mar; 48(1):11-26. PubMed ID: 33648041
[TBL] [Abstract][Full Text] [Related]
6. The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer.
Blondeaux E; Massarotti C; Fontana V; Poggio F; Arecco L; Fregatti P; Bighin C; Giannubilo I; Ruelle T; Razeti MG; Boni L; Anserini P; Del Mastro L; Lambertini M
Front Oncol; 2021; 11():690320. PubMed ID: 34150661
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients.
Conte B; Del Mastro L
Minerva Ginecol; 2017 Aug; 69(4):350-356. PubMed ID: 28398024
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
9. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.
Lambertini M; Horicks F; Del Mastro L; Partridge AH; Demeestere I
Cancer Treat Rev; 2019 Jan; 72():65-77. PubMed ID: 30530271
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
Blumenfeld Z; Zur H; Dann EJ
Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
[TBL] [Abstract][Full Text] [Related]
11. The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies.
Lei YY; Yeo W
Expert Opin Drug Saf; 2021 Oct; 20(10):1163-1175. PubMed ID: 33951990
[No Abstract] [Full Text] [Related]
12. Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis.
Senra JC; Roque M; Talim MCT; Reis FM; Tavares RLC
Ultrasound Obstet Gynecol; 2018 Jan; 51(1):77-86. PubMed ID: 29055060
[TBL] [Abstract][Full Text] [Related]
13. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
14. Controversies over the use of GnRH agonists for reduction of chemotherapy-induced gonadotoxicity.
Garrido-Oyarzún MF; Castelo-Branco C
Climacteric; 2016 Dec; 19(6):522-525. PubMed ID: 27644002
[TBL] [Abstract][Full Text] [Related]
15. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists.
Hickman LC; Valentine LN; Falcone T
Am J Obstet Gynecol; 2016 Oct; 215(4):415-22. PubMed ID: 27422055
[TBL] [Abstract][Full Text] [Related]
16. Medical approaches to preservation of fertility in female cancer patients.
Del Mastro L; Giraudi S; Levaggi A; Pronzato P
Expert Opin Pharmacother; 2011 Feb; 12(3):387-96. PubMed ID: 21254946
[TBL] [Abstract][Full Text] [Related]
17. Controversies Regarding Ovarian Suppression and Infertility in Early Stage Breast Cancer.
Durrani S; Heena H
Cancer Manag Res; 2020; 12():813-817. PubMed ID: 32104064
[TBL] [Abstract][Full Text] [Related]
18. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Blumenfeld Z
Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis.
Li ZY; Dong YL; Cao XZ; Ren SS; Zhang Z
Menopause; 2022 Sep; 29(9):1093-1100. PubMed ID: 35917530
[TBL] [Abstract][Full Text] [Related]
20. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
